Cargando…

Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy

Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are an adult-onset progressive neurodegenerative disorder that are known to display diverse clinical features and disease progression. We aim to characterize the clinical features and disease progression in patients with MSA and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sang-Wook, Koh, Seong-Beom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Movement Disorder Society 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027659/
https://www.ncbi.nlm.nih.gov/pubmed/24868413
http://dx.doi.org/10.14802/jmd.12010
_version_ 1782316977046421504
author Lee, Sang-Wook
Koh, Seong-Beom
author_facet Lee, Sang-Wook
Koh, Seong-Beom
author_sort Lee, Sang-Wook
collection PubMed
description Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are an adult-onset progressive neurodegenerative disorder that are known to display diverse clinical features and disease progression. We aim to characterize the clinical features and disease progression in patients with MSA and PSP by using a number of relevant disability milestones in Koreans. Forty-one patients with MSA and 14 patients with PSP had been enrolled. The mean age at onset of MSA-C, MSA-P and PSP was 56.7 ± 7.8, 62.5 ± 8.0, 68.9 ± 6.1 years respectively. The most commonly reported symptom at disease onset is disequilibrium/dizziness in MSA-C, tremor in MSA-P and frequent falling in PSP. The mean duration of reaching milestones after disease onset in MSA-C were as followings: 20.8 (urinary incontinence), 22.9 (frequent falling), 27.8 (wheelchair bound), 31.8 (dysarthria) and 35.8 months (diagnosis). The mean duration of reaching milestones after disease onset were 22.0 (urinary incontinence), 32.6 (frequent falling and diagnosis), 41.2 (dysarthria), 61.4 months (wheelchair bound) in MSA-P and 16.8 (dysarthria), 21.6 (diagnosis), 21.7 (frequent falling), 24.0 months (wheel chair bound) in PSP. In the case of MSA, dizziness may occur for the first time. Thus, when the patient complains of non-specific dizziness, a follow-up examination to distinguish it from MSA can be helpful. There was a trend for patients with MSA-C to reach more disability milestones than in MSA-P and PSP before diagnosis. It may explain why patients with MSA-C are required more detail history taking and neurologic examination at an earlier stage.
format Online
Article
Text
id pubmed-4027659
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher The Korean Movement Disorder Society
record_format MEDLINE/PubMed
spelling pubmed-40276592014-05-27 Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy Lee, Sang-Wook Koh, Seong-Beom J Mov Disord Original Article Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are an adult-onset progressive neurodegenerative disorder that are known to display diverse clinical features and disease progression. We aim to characterize the clinical features and disease progression in patients with MSA and PSP by using a number of relevant disability milestones in Koreans. Forty-one patients with MSA and 14 patients with PSP had been enrolled. The mean age at onset of MSA-C, MSA-P and PSP was 56.7 ± 7.8, 62.5 ± 8.0, 68.9 ± 6.1 years respectively. The most commonly reported symptom at disease onset is disequilibrium/dizziness in MSA-C, tremor in MSA-P and frequent falling in PSP. The mean duration of reaching milestones after disease onset in MSA-C were as followings: 20.8 (urinary incontinence), 22.9 (frequent falling), 27.8 (wheelchair bound), 31.8 (dysarthria) and 35.8 months (diagnosis). The mean duration of reaching milestones after disease onset were 22.0 (urinary incontinence), 32.6 (frequent falling and diagnosis), 41.2 (dysarthria), 61.4 months (wheelchair bound) in MSA-P and 16.8 (dysarthria), 21.6 (diagnosis), 21.7 (frequent falling), 24.0 months (wheel chair bound) in PSP. In the case of MSA, dizziness may occur for the first time. Thus, when the patient complains of non-specific dizziness, a follow-up examination to distinguish it from MSA can be helpful. There was a trend for patients with MSA-C to reach more disability milestones than in MSA-P and PSP before diagnosis. It may explain why patients with MSA-C are required more detail history taking and neurologic examination at an earlier stage. The Korean Movement Disorder Society 2012-10-30 2012-10 /pmc/articles/PMC4027659/ /pubmed/24868413 http://dx.doi.org/10.14802/jmd.12010 Text en Copyright © 2012 The Korean Movement Disorder Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Sang-Wook
Koh, Seong-Beom
Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy
title Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy
title_full Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy
title_fullStr Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy
title_full_unstemmed Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy
title_short Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy
title_sort clinical features and disability milestones in multiple system atrophy and progressive supranuclear palsy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027659/
https://www.ncbi.nlm.nih.gov/pubmed/24868413
http://dx.doi.org/10.14802/jmd.12010
work_keys_str_mv AT leesangwook clinicalfeaturesanddisabilitymilestonesinmultiplesystematrophyandprogressivesupranuclearpalsy
AT kohseongbeom clinicalfeaturesanddisabilitymilestonesinmultiplesystematrophyandprogressivesupranuclearpalsy